Remove Biopharma Remove Healthcare Remove Leads Remove Pharmaceutical products
article thumbnail

Getting ahead of regulatory changes around PFAS in pharmaceutical packaging

Clarivate

Nitrosamines have garnered significant attention from the pharmaceutical industry due to their detection in commonly prescribed medications for conditions like type 2 diabetes, high blood pressure, and heartburn. [1] Manufacturers, healthcare providers, and consumers alike face the need to quickly adapt.

article thumbnail

Practical advice for Early Scientific Advice (ESA) in HTA submissions

pharmaphorum

A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence generation to support the design of an asset. In recent years, the biopharma market has become progressively complex.